Last reviewed · How we verify
BAY 3389934
At a glance
| Generic name | BAY 3389934 |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY 3389934 CI brief — competitive landscape report
- BAY 3389934 updates RSS · CI watch RSS
- Bayer portfolio CI